版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、The Clinical Application of Corticosteroids in Ulcerative Colitis,rui nan Wang,Two parts,The introduction of Ulcerative colitisThe clinical application of Corticosteroids in Ulcerative colitis,Ulcerative coliti
2、s,Definition:Chronic non-specific colitisInflammation of the mucosa and submucosa of the large intestine,Features:,diarrhea with feces containing mucus, pus and blood, abdominal pain and tenesmus; and recurre
3、nce is commonMostly seen in 20-50 years of age, and in EuropeLess common in China,,,,,Infection,Environmental factors,Genetic susceptible,,Immune & inflammatory system,,,Etiology and pathogenesis,,Location: rectum
4、 and sigmoid colon, then descending, transverse or pan-colon, even terminal ileumMucosa diffused inflammation with edema, congestion and local bleedings.,Pathology,,,Infiltration of lymphocytes, plasma cells, eosinophil
5、ic cells and neutrophilic cells in mucosaCryptic abscess and superficial ulcersInflammatory polyps or pseudopolyps;,,,UC,UC,Cryptic abscess in UC,,Clinical Manifestations,,Symptoms: diarrhea abdominal pain, others :
6、tenesmus, anorexia, nausea and vomiting Signs: tenderness in the left hypogastrium and rebound tenderness,Manifestations of digestive system,Systemic manifestations,fever,tachycardia,Anemia, malnutrition, volume depleti
7、on, disturbance in acid-basebalance and hypoalbuminemia in advanced patients,Extra-intestinal manifestations,erythema nodosum, arthritis, ankylosing spondylitis, iritis,episcleritis, conjunctivitis, ulcers of oral mucosa
8、, chronic active hepatitis and so on.,erythema nodosum,,,A.course classificationinitial typechronic relapse typechronic permanent type acute and fulminant type,,Clinical classification,UC,B.Extent classification
9、 (1) mild type (2) moderate type (3)severe type,Classification,,UC,C.range classificationProctitis or proctosigmoiditis:40-50%Left-sided or intermediate colitis :30-40%Pancolitis:20% D.period c
10、lassificationActive phaseAlleviative phase,Classification,,UC,,UC,endoscopic examination,Diseased mucosa: hyperemic and edematous, blood vessels not clear-cut, mucosa erosions and multiple shallow ulcers; rough, fragi
11、le, bleeding easily granular, pus; pseudopolyps seen,Mucosa irregularity, saw-tooth like, loss of haustrations, shortening of colon and pseudopolyps formationContraindicated in fulminant type,UC,Barium enema,typical sy
12、mptoms+one of endoscopic appearances and biopsy (or one of x-ray barium enema signs)+elimination of other alike disease Notice:1.symptoms are not typical,while endoscopic appearances are typical-diagnosis 2.symptoms ar
13、e typical, while endoscopic appearances are not typical-suspect,Diagnosis,Treatment,General treatment,Drug treatment,Sulfasalazine,Corticosteroids,Immune inhibitor,,,,,First choice,Severe patients,Surgical therapy,,,,Ind
14、ications: abscess formation, canceration, perforation, fistula, mega-colon and refractory colitis, failure of medical therapy etc,Second part,The clinical application of Corticosteroids in Ulcerative colitis,Finding,CO
15、RTISONE IN ULCERATIVE COLITIS FINAL REPORT ON A THERAPEUTIC TRIAL,BRITISH MEDICAL JOURNAL On OCTOBER 29 1955,S. C. TRUELOVE, M.D., M.R.C.P. AND L. J. WITTS, M.D., F.R.C.P.,Conclusion,the patients receiving cortisone en
16、joyed a clear-cut advantage over the patients on a dummy preparation. About two out of every five patients on cortisone therapy were in clinical remission at the end of six weeks' treatment, compared with less than
17、one out of every six patients receiving the inert therapy.,,Among the patients treated with cortisone those in their first attack have fared somewhat better than those in relapse.,How to decide the dose of Corticost
18、eroids,,The American Journal of GASTROENTEROLOGY,Ulcerative Colitis Practice Guidelines in Adults,by American College of Gastroenterology Practic Parameters Committee,Ulcerative Colitis Practice Guidelines in Adults,O
19、ral prednisone shows a dose response effect between 20 and 60 mg per day , with 60 mg per day modestly more effective than 40 mg per day but at the expense of greater side-effects .,Ulcerative Colitis Practice Guidelines
20、 in Adults,No randomized trials have studied Corticosteroids taper schedules; most recommendations have advised 40 – 60 mg per day until significant clinical improvement occurs and then a dose taper of 5 – 10 mg weekly
21、until a daily dose of 20 mg is reached. At this point tapering generally proceeds at 2.5 mg per week.,,The therapeutic plan is determined by the Patients condition and preferences,severe and fulminant type,For patients
22、 who suffer from severe and fulminant type of UC :intravenous injection Corticosteroids is First choice , recommend dosage hydrocortisone 300mg or meprednisone 60mg。,mild and moderate type with largely lesion,For mild a
23、nd moderate patient, First choice oral Sulfasalazine ,while it is not effective,recommend oral prednisone 20~60 mg/d,mild and moderate type with Distal lesion,Corticosteroids topical therapies,Effect of topical administr
24、ation of budesonide and tranditional corticosteroids on active distal ulcerative colitis or proctitis,Shang hai Jiao tong University School of Medicine,Research from,Conclusion,The effects of budesonide and traditional c
25、orticosteroids on active distal Ulcerative colitis or Proctitis are similar.However, budesonide maybe Preferable to traditional corticosteroids ,since its inhibitory effect on Plasma cortisol level is lower than traditi
26、onal corticosteroids.,adverse effects,Such as cushingoid features, emotional and psychiatric disturbances, infections, glaucoma.Complicationsinclude gastroduodenal mucosal injury, impaired wound healing, and metabolic
27、bone disease.,steroid-dependency,Although short term control of symptoms can be achieved with steroid treatment, followed by recurrence during alleviating dose or stopping administration. this pattern of drug response,kn
28、own as steroid-dependency.,The therapeutic plan for steroid-dependency,Azathioprine 2-2.5mg/kg*dCyclosporin therapy for severe ulcerative colitisInfliximab ——could not only maintain the clinical remission in UC patie
29、nts,but also decrease the colon resection rate for patients with moderate to severe refractory UC,Else therapies,intestinal stem cells antibiotics If failure of medical therapy ,the Surgical therapy should be taken.,,T
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫(kù)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 潰瘍性結(jié)腸炎
- 《潰瘍性結(jié)腸炎》
- 潰瘍性結(jié)腸炎詳解
- 潰瘍性結(jié)腸炎課件
- 潰瘍性結(jié)腸炎查房
- 潰瘍性結(jié)腸炎診治
- 潰瘍性結(jié)腸炎新
- 自學(xué)潰瘍性結(jié)腸炎
- 潰瘍性結(jié)腸炎的護(hù)理
- 潰瘍性結(jié)腸炎和潰瘍性結(jié)腸炎相關(guān)癌的有關(guān)基因改變.pdf
- 潰瘍性結(jié)腸炎的治療
- 潰瘍性結(jié)腸炎診斷標(biāo)準(zhǔn)
- 潰瘍性結(jié)腸炎授課講稿
- 艾灸治療潰瘍性結(jié)腸炎
- 潰瘍性結(jié)腸炎的食療藥膳
- 潰瘍性結(jié)腸炎的合理用藥
- 潰瘍性結(jié)腸炎的藥物治療
- 指南之潰瘍性結(jié)腸炎
- 潰瘍性結(jié)腸炎診治進(jìn)展
- 潰瘍性結(jié)腸炎的護(hù)理講解
評(píng)論
0/150
提交評(píng)論